The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Supplementary Issue: Biomarkers and their Essential Role in the Development of Personalised Therapies (A)
Henri C, Heinonen T and Tardif JC
Biomark Cancer. 2016; 8(Suppl 2): 39–45
CARDIONCOLOGY.ORG ABSTRACT:
Although cancer survival rates have improved, cancer therapies are still associated with cardiac toxicity especially the anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib).
Monitoring of cardiac toxicity is commonly performed by assessment of left ventricular (LV) ejection fraction, which requires a significant amount of myocardial damage to allow detection of cardiac toxicity. Accordingly, this creates the impetus to search for more sensitive and reproducible biomarkers of cardiac toxicity after cancer therapy. Different biomarkers for cardiotoxicity have been proposed in particular troponin release resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in LV filling pressure and wall stress.
The purpose of this article is to review the available data to determine the role of biomarkers in decreasing the risk of cardiac toxicity after cancer therapy.
© All Rights Reserved
Image source: https://acutecaretesting.org/en/articles/how-to-use-high-sensitivity-cardiac-troponin-assays-most-effectively-in-clinical-practice